On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

Mer­ck has notched an ap­proval for us­ing Keytru­da to treat a bio­mark­er-based sub­set of first-line col­orec­tal can­cer pa­tients with un­re­sectable or metasta­t­ic tu­mors, as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER